Literature DB >> 2104765

Noncoagulation inhibitory factor VIII antibodies after induction of tolerance to factor VIII in hemophilia A patients.

I M Nilsson1, E Berntorp, O Zettervall, B Dahlbäck.   

Abstract

We recently described tolerance induction with factor VIII/IX, cyclophosphamide, and high-dose intravenous IgG in hemophilia A or B patients with coagulation inhibitory antibodies. Circulating noninhibitory antibodies complexed with factor IX have been demonstrated in tolerant hemophilia B patients. Similar findings are now described in six tolerant hemophilia A patients. Complexes between factor VIII and the 'tolerant' antibody were demonstrated by subjecting plasma to gel filtration chromatography, void fractions containing factor VIII/vWF complexes being collected and adsorbed to protein A. Using 125I-labeled F(ab')2 fragments against IgG subclass and factor VIII antigen, complexes between an IgG4 antibody and factor VIII were found to adsorb to protein A. After infusion of factor VIII to tolerant patients, all factor VIII circulated in complex with IgG4 antibody. In three of the patients, the 'tolerant' antibodies inhibited an ELISA specific for factor VIII light chain but, unlike the pretolerant antibodies, did not bind radiolabeled factor VIII heavy chain. Although after induction of tolerance the patients still have circulating IgG4 antibodies against factor VIII, the antibodies differ in specificity, lack coagulation inhibitory activity, and do not enhance the rate of elimination of factor VIII.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2104765

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  11 in total

1.  IgG Antibodies Against Factor VIII in Normal Individuals.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

2.  Healthy subjects produce both anti-factor VIII and specific anti-idiotypic antibodies.

Authors:  J G Gilles; J M Saint-Remy
Journal:  J Clin Invest       Date:  1994-10       Impact factor: 14.808

Review 3.  The relevance of pharmacokinetics in the development of biotechnology products.

Authors:  S Toon
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1996 Apr-Jun       Impact factor: 2.441

4.  Tolerance to factor VIII inhibitors in hemophilia A patients: a French twist.

Authors:  V Pascual; J D Capra
Journal:  J Clin Invest       Date:  1996-03-15       Impact factor: 14.808

Review 5.  Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia.

Authors:  S Björkman; E Berntorp
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 6.  Current options and new developments in the treatment of haemophilia.

Authors:  Trisha Wong; Michael Recht
Journal:  Drugs       Date:  2011-02-12       Impact factor: 9.546

Review 7.  Laboratory testing for factor VIII and IX inhibitors in haemophilia: A review.

Authors:  C H Miller
Journal:  Haemophilia       Date:  2018-02-15       Impact factor: 4.287

8.  Characterization of a monoclonal anti-idiotype antibody to human anti-factor VIII antibodies.

Authors:  B C Lubahn; H M Reisner
Journal:  Proc Natl Acad Sci U S A       Date:  1990-11       Impact factor: 11.205

9.  Effect of HLA DR epitope de-immunization of Factor VIII in vitro and in vivo.

Authors:  Leonard Moise; Chang Song; William D Martin; Ryan Tassone; Anne S De Groot; David W Scott
Journal:  Clin Immunol       Date:  2011-12-08       Impact factor: 3.969

10.  Antibodies to factor VIII in plasma of patients with hemophilia A and normal subjects.

Authors:  J Batlle; E Gómez; E Rendal; J Torea; E Lourés; M Couselo; P Vila; C Sedano; X Tusell; M Magallón; M Quintana; R González-Boullosa; M F López-Fernández
Journal:  Ann Hematol       Date:  1996-05       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.